The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...

Novo Nordisk, the Danish drugmaker behind the popular obesity drug Wegovy, warns of fierce competition and market pressures, potentially leading to layoffs. As compounders produce cheaper copycats, U.

Experts reveal potential unintended Ozempic side effect – and whether we should worry - Researchers found Ozempic-induced weight loss decreased muscle mass by about 10 per cent ...